Abstract Background JAK2V617F is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. However, it has also been found in many other hematological diseases, and some studies even detected the presence of JAK2V617F in normal blood samples. This casts doubt on the primary role of JAK2V617F in the pathogenesis of MPNs and its diagnostic value. Methods In the present study, we analyzed JAK2V617F positivity with 232 normal blood samples and 2663 patient blood, bone marrow, and amniotic fluid specimens obtained from a clinical genetics laboratory by using a simple DNA extraction method and a sensitive nested allele-specific PCR strategy. Results We found JAK2V617F pr...
Background and Aim : Myeloproliferative neoplasms are clonal and heterogeneous disorders of hematopo...
Objectives: Arterial and venous thrombotic events are more commonly observed in patients with myelop...
Background and Aim: The JAK2 is an acquired mutation that is observed in majority of patients with c...
Abstract Background Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chron...
Since low JAK2V617F allele burden (AB) has been detected also in healthy subjects, its clinical inte...
Objective/backgroundMyeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow stem ce...
Introduction: This study aimed to verify the association between the JAK2 46/1 haplotype (V617F posi...
found in patients with myeloprolifera-tive disorders (MPDs), including most with polycythemia vera (...
This study aimed to verify the association between the JAK2 46/1 haplotype (V617F positive) and some...
Introduction: The myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characte...
In Ph- myeloproliferative neoplasms, the quantification of the JAK2V617F transcripts may provide som...
Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic m...
BACKGROUND/AIMS: The JAK2(V617F) mutation, which has been found in patients with myeloproliferative ...
INTRODUCTION: Currently, the JAK2V617F allele quantification in Ph- MPN is performed on genomic DNA....
OBJECTIVE: The JAK2 46/1 haplotype has recently been described as a major contributing factor to the...
Background and Aim : Myeloproliferative neoplasms are clonal and heterogeneous disorders of hematopo...
Objectives: Arterial and venous thrombotic events are more commonly observed in patients with myelop...
Background and Aim: The JAK2 is an acquired mutation that is observed in majority of patients with c...
Abstract Background Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chron...
Since low JAK2V617F allele burden (AB) has been detected also in healthy subjects, its clinical inte...
Objective/backgroundMyeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow stem ce...
Introduction: This study aimed to verify the association between the JAK2 46/1 haplotype (V617F posi...
found in patients with myeloprolifera-tive disorders (MPDs), including most with polycythemia vera (...
This study aimed to verify the association between the JAK2 46/1 haplotype (V617F positive) and some...
Introduction: The myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characte...
In Ph- myeloproliferative neoplasms, the quantification of the JAK2V617F transcripts may provide som...
Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic m...
BACKGROUND/AIMS: The JAK2(V617F) mutation, which has been found in patients with myeloproliferative ...
INTRODUCTION: Currently, the JAK2V617F allele quantification in Ph- MPN is performed on genomic DNA....
OBJECTIVE: The JAK2 46/1 haplotype has recently been described as a major contributing factor to the...
Background and Aim : Myeloproliferative neoplasms are clonal and heterogeneous disorders of hematopo...
Objectives: Arterial and venous thrombotic events are more commonly observed in patients with myelop...
Background and Aim: The JAK2 is an acquired mutation that is observed in majority of patients with c...